Corteva Falls as Vylor Spin-Off Resets Share Price

Corteva (CTVA) is down 84.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears to be driven mainly by Corteva completing the separation of its seed and genetics business, Vylor, rather than by a sudden deterioration in the remaining company’s operations. On October 1, 2026, Corteva distributed Vylor shares to eligible stockholders, so Corteva stock began trading without that business embedded in its price.

Details:

Corteva completed the separation on October 1, 2026 through a pro rata distribution of all outstanding Vylor shares to Corteva holders of record from September 24, 2026.

Investors were set to receive one share of Vylor common stock for each Corteva share held on the record date, which means part of the prior combined value shifted into the new standalone stock.

Vylor was scheduled to begin regular-way trading on the NYSE on October 1, 2026 under the ticker VYLR, creating a cleaner post-spin valuation for the remaining Corteva business.

Corteva had previously said the separation would create two independent public companies, so the move looks consistent with a distribution-related repricing rather than a typical selloff tied to earnings or guidance.

Sources:

Corteva, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CTVA Hedge Fund Activity

We have seen 611 institutional investors add shares of $CTVA stock to their portfolio, and 617 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS added 6,925,682 shares (+19.2%) to their portfolio in Q2 2026, for an estimated $586,536,008
WELLINGTON MANAGEMENT GROUP LLP added 6,881,875 shares (+941.7%) to their portfolio in Q2 2026, for an estimated $582,825,993
JPMORGAN CHASE & CO added 6,423,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $543,978,860
FMR LLC added 6,100,388 shares (+17.4%) to their portfolio in Q2 2026, for an estimated $516,641,859
WELLS FARGO & COMPANY/MN removed 4,946,270 shares (-80.5%) from their portfolio in Q2 2026, for an estimated $418,899,606
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,543,939 shares (+inf%) to their portfolio in Q2 2026, for an estimated $384,826,193
NORGES BANK removed 2,022,898 shares (-26.9%) from their portfolio in Q2 2026, for an estimated $171,319,231

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CTVA Congressional Stock Trading

Members of Congress have traded $CTVA stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CTVA stock by members of Congress over the last 6 months:

SENATOR GARY C. PETERS sold up to $50,000 on 04/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$CTVA Price Targets

Multiple analysts have issued price targets for $CTVA recently. We have seen 8 analysts offer price targets for $CTVA in the last 6 months, with a median target of $90.5.

Here are some recent targets:

John Roberts from Mizuho set a target price of $96.0 on 07/02/2026
Benjamin Theurer from Barclays set a target price of $91.0 on 06/11/2026
Joshua Spector from UBS set a target price of $86.0 on 06/09/2026
Vincent Andrews from Morgan Stanley set a target price of $95.0 on 05/28/2026
Patrick Cunningham from Citigroup set a target price of $85.0 on 05/07/2026
Arun Viswanathan from RBC Capital set a target price of $95.0 on 04/24/2026
Kristen Owen from Oppenheimer set a target price of $89.0 on 04/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.